Syndax Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or ...
Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
US stock futures traded in a mixed fashion Monday, with traders awaiting more corporate earnings as well as speeches from a number of Fed officials. Here are some of the biggest premarket US stock ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback